Why 70% Stop GLP-1s: The Real Discontinuation Data
New real-world data reveals massive dropout rates from GLP-1 medications — and the reasons aren't what you'd expect from clinical trials.
Published May 28, 2026·4 min read·Evidence: Peer Reviewed
What They Found
This analysis examined real-world discontinuation patterns for GLP-1 receptor agonists and tirzepatide, revealing significantly higher dropout rates than clinical trials suggest. The study tracked patients across multiple healthcare systems to identify both the timing and reasons for stopping these medications.
Why It Matters
The disconnect between clinical trial adherence and real-world persistence is massive with GLP-1 medications. While pivotal trials show 80-90% completion rates, real-world studies consistently demonstrate 50-70% discontinuation within the first year. This isn't just about side effects — though GI intolerance remains the leading cause of early discontinuation.
The mechanism-based reasons for stopping matter clinically. Nausea and vomiting typically peak at weeks 4-8 as GLP-1 receptors in the area postrema become saturated, but insurance barriers and cost issues create discontinuation patterns that have nothing to do with drug tolerance. Tirzepatide's dual GLP-1/GIP mechanism may offer better GI tolerability, but access restrictions limit its real-world adoption.
What's particularly concerning is the rebound effect post-discontinuation. GLP-1 medications work by slowing gastric emptying and increasing satiety signaling, but these effects reverse within 4-6 weeks of stopping. Patients who discontinue often regain 60-70% of lost weight within six months, suggesting that intermittent use patterns — common in real-world settings — may be metabolically counterproductive.
What I'd Watch For
Without access to the full methodology, I can't assess how they controlled for planned vs. unplanned discontinuation or whether they tracked compounding pharmacy usage. Many patients are switching to compounded versions due to cost, which wouldn't appear in traditional pharmacy records.
The next critical study needs to stratify discontinuation by reason and track metabolic outcomes post-stopping. We need data on whether structured discontinuation protocols can maintain benefits better than abrupt cessation.
Bottom Line
Real-world GLP-1 discontinuation rates are sobering and highlight the gap between clinical efficacy and practical sustainability. Until we address access barriers and develop better discontinuation strategies, these medications will remain effective for the minority who can stay on them long-term.